Physician profile
Mark D Uhl
NPI 1912979501
$1,845.73
in general payments reported to CMS, 2019-2025
24 companies · $472 in 2025
The $472 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $107 · 2021: $202 · 2022: $266 · 2023: $300 · 2024: $305 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $682.27 | 2019-2025 | Trulance, Xifaxan |
| Abbvie INC. | $435.76 | 2021-2025 | Skyrizi, Rinvoq, Vraylar |
| Gilead Sciences, INC. | $102.24 | 2019-2022 | |
| Madrigal Pharmaceuticals | $101.64 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $54.66 | 2020 | |
| Celltrion USA INC. | $51.37 | 2025 | Vegzelma |
| Lilly USA, LLC | $46.77 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $45.55 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.76 | 2019 | |
| Redhill Biopharma INC. | $32.03 | 2021 | |
| Janssen Biotech, INC. | $29.09 | 2023-2024 | Stelara, Remicade, Simponi |
| Novo Nordisk INC | $28.42 | 2020-2025 | Wegovy |
| Inspire Medical Systems, INC. | $27.56 | 2024 | Inspire |
| Hologic Sales and Service, LLC | $18.42 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.15 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17.87 | 2020 | |
| Biocompatibles, INC. | $17.63 | 2019 | |
| Evoke Pharma, INC. | $16.65 | 2025 | |
| Pfizer INC. | $16.56 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $14.98 | 2023 | Dupixent |
| Qol Medical, LLC | $14.48 | 2022 | |
| Amgen INC. | $13.79 | 2022 | |
| Intercept Pharmaceuticals, INC. | $13.58 | 2025 | |
| Allergan, INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Uhl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.